Search Results - "van de Winkel, Jan G J"

IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis by Skov, Lone, Beurskens, Frank J, Zachariae, Claus O. C, Reitamo, Sakari, Teeling, Jessica, Satijn, David, Knudsen, Kim M, Boot, Elmieke P. J, Hudson, Debra, Baadsgaard, Ole, Parren, Paul W. H. I, van de Winkel, Jan G. J

“…IL-8 is a chemokine that has been implicated in a number of inflammatory diseases involving neutrophil activation. HuMab 10F8 is a novel fully human mAb…”
Get full text

IGA FC RECEPTORS by Monteiro, Renato C, van de Winkel, Jan G. J

“…The IgA receptor family comprises a number of surface receptors including the polymeric Ig receptor involved in epithelial transport of IgA/IgM, the myeloid…”
Get full text

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 by Teeling, Jessica L, Mackus, Wendy J. M, Wiegman, Luus J. J. M, van den Brakel, Jeroen H. N, Beers, Stephen A, French, Ruth R, van Meerten, Tom, Ebeling, Saskia, Vink, Tom, Slootstra, Jerry W, Parren, Paul W. H. I, Glennie, Martin J, van de Winkel, Jan G. J

“…We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of…”
Get full text

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors by de Weers, Michel, Tai, Yu-Tzu, van der Veer, Michael S, Bakker, Joost M, Vink, Tom, Jacobs, Daniëlle C H, Oomen, Lukas A, Peipp, Matthias, Valerius, Thomas, Slootstra, Jerry W, Mutis, Tuna, Bleeker, Wim K, Anderson, Kenneth C, Lokhorst, Henk M, van de Winkel, Jan G J, Parren, Paul W H I

“…CD38, a type II transmembrane glycoprotein highly expressed in hematological malignancies including multiple myeloma (MM), represents a promising target for…”
Get full text

Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor by Dechant, Michael, Beyer, Thomas, Schneider-Merck, Tanja, Weisner, Wencke, Peipp, Matthias, van de Winkel, Jan G. J, Valerius, Thomas

“…IgA is the most abundantly produced Ab isotype in humans, but its potential as immunotherapeutic reagent has hardly been explored. In this study, we describe…”
Get full text

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG by van der Poel, Cees E., Karssemeijer, Roos A., Boross, Peter, van der Linden, Joke A., Blokland, Miranda, van de Winkel, Jan G.J., Leusen, Jeanette H.W.

“…FcγRI is the sole high-affinity immunoglobulin G (IgG) receptor on leukocytes. Its role in immunity and the clearance of opsonized particles has been…”
Get full text

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage by Schneider-Merck, Tanja, Lammerts van Bueren, Jeroen J, Berger, Sven, Rossen, Kai, van Berkel, Patrick H.C, Derer, Stefanie, Beyer, Thomas, Lohse, Stefan, Bleeker, Wim K, Peipp, Matthias, Parren, Paul W. H. I, van de Winkel, Jan G. J, Valerius, Thomas, Dechant, Michael

“…Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of action for immunotherapy with human IgG1 but not IgG2 Abs. The…”
Get full text

Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy by Bleeker, Wim K, Lammerts van Bueren, Jeroen J, van Ojik, Heidi H, Gerritsen, Arnout F, Pluyter, Marielle, Houtkamp, Mischa, Halk, Ed, Goldstein, Joel, Schuurman, Janine, van Dijk, Marc A, van de Winkel, Jan G. J, Parren, Paul W. H. I

“…Epidermal growth factor receptor (EGF-R) overexpression is common in a large number of solid tumors and represents a negative prognostic indicator…”
Get full text

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells by Beum, Paul V, Peek, Elizabeth M, Lindorfer, Margaret A, Beurskens, Frank J, Engelberts, Patrick J, Parren, Paul W H I, van de Winkel, Jan G J, Taylor, Ronald P

“…We previously reported that 1 h after infusion of CD20 mAb rituximab in patients with chronic lymphocytic leukemia (CLL), >80% of CD20 was removed from…”
Get full text

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange by van der Neut Kolfschoten, Marijn, Schuurman, Janine, Losen, Mario, Bleeker, Wim K., Martínez-Martínez, Pilar, Vermeulen, Ellen, Bleker, Tamara H. den, Wiegman, Luus, Vink, Tom, Aarden, Lucien A., De Baets, Marc H., van de Winkel, Jan G. J., Aalberse, Rob C., Parren, Paul W. H. I.

“…Antibodies play a central role in immunity by forming an interface with the innate immune system and, typically, mediate proinflammatory activity. We describe…”
Get full text

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells by Peipp, Matthias, Lammerts van Bueren, Jeroen J., Schneider-Merck, Tanja, Bleeker, Wim W.K., Dechant, Michael, Beyer, Thomas, Repp, Roland, van Berkel, Patrick H.C., Vink, Tom, van de Winkel, Jan G.J., Parren, Paul W.H.I., Valerius, Thomas

“…Glycosylation of the antibody Fc fragment is essential for Fc receptor–mediated activity. Carbohydrate heterogeneity is known to modulate the activity of…”
Get full text

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis by Beum, Paul V, Lindorfer, Margaret A, Beurskens, Frank, Stukenberg, P. Todd, Lokhorst, Henk M, Pawluczkowycz, Andrew W, Parren, Paul W. H. I, van de Winkel, Jan G. J, Taylor, Ronald P

“…Binding of the CD20 mAb rituximab (RTX) to B lymphocytes in normal human serum (NHS) activates complement (C) and promotes C3b deposition on or in close…”
Get full text

Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing by Lohse, Stefan, Derer, Stefanie, Beyer, Thomas, Klausz, Katja, Peipp, Matthias, Leusen, Jeanette H W, van de Winkel, Jan G J, Dechant, Michael, Valerius, Thomas

“…Dimeric IgA Abs contribute significantly to the humoral part of the mucosal immune system. However, their potential as immunotherapeutic agent has hardly been…”
Get full text

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface by Diebolder, Christoph A., Beurskens, Frank J., de Jong, Rob N., Koning, Roman I., Strumane, Kristin, Lindorfer, Margaret A., Voorhorst, Marleen, Ugurlar, Deniz, Rosati, Sara, Heck, Albert J. R., van de Winkel, Jan G. J., Wilson, Ian A., Koster, Abraham J., Taylor, Ronald P., Saphire, Erica Ollmann, Burton, Dennis R., Schuurman, Janine, Gros, Piet, Parren, Paul W. H. I.

“…Complement activation by antibodies bound to pathogens, tumors, and self antigens is a critical feature of natural immune defense, a number of disease…”
Get full text

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange by Labrijn, Aran F, Meesters, Joyce I, de Goeij, Bart E C G, van den Bremer, Ewald T J, Neijssen, Joost, van Kampen, Muriel D, Strumane, Kristin, Verploegen, Sandra, Kundu, Amitava, Gramer, Michael J, van Berkel, Patrick H C, van de Winkel, Jan G J, Schuurman, Janine, Parren, Paul W H I

“…The promise of bispecific antibodies (bsAbs) to yield more effective therapeutics is well recognized; however, the generation of bsAbs in a practical and…”
Get full text

Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors by Otten, Marielle A, Rudolph, Esther, Dechant, Michael, Tuk, Cornelis W, Reijmers, Rogier M, Beelen, Robert H. J, van de Winkel, Jan G. J, van Egmond, Marjolein

“…Antitumor Abs are promising therapeutics for cancer. Currently, most Ab-based therapies focus on IgG Ab, which interact with IgG FcR (FcgammaR) on effector…”
Get full text

Working Mechanism of Immunoglobulin A1 (IgA1) Protease: Cleavage of IgA1 Antibody to Neisseria meningitidis PorA Requires De Novo Synthesis of IgA1 Protease by Vidarsson, Gestur, Overbeeke, Natasja, Stemerding, Annette M, van den Dobbelsteen, Germie, van Ulsen, Peter, van der Ley, Peter, Kilian, Mogens, van de Winkel, Jan G. J

“…Neisseria meningitidis secretes a protease that specifically cleaves the hinge region of immunoglobulin A1 (IgA1), releasing the effector (Fc) domain of IgA1…”
Get full text

antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility by Lammerts van Bueren, Jeroen J, Bleeker, Wim K, Brännström, Annika, von Euler, Anne, Jansson, Magnus, Peipp, Matthias, Schneider-Merck, Tanja, Valerius, Thomas, van de Winkel, Jan G.J, Parren, Paul W.H.I

“…The epidermal growth factor receptor (EGFR) activates cellular pathways controlling cell proliferation, differentiation, migration, and survival. It thus…”
Get full text

N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG by van Berkel, Patrick H. C., Gerritsen, Jolanda, Perdok, Gerrard, Valbjørn, Jesper, Vink, Tom, van de Winkel, Jan G. J., Parren, Paul W. H. I.

“…We studied the variations in N‐linked glycosylation of human IgG molecules derived from 105 different stable cell lines each expressing one of the six…”
Get full text

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti‐CD20 antibody by Bleeker, Wim K., Munk, Martin E., Mackus, Wendy J. M., Van Den Brakel, Jeroen H. N., Pluyter, Marielle, Glennie, Martin J., Van De Winkel, Jan G. J., Parren, Paul W. H. I.

“…Summary We evaluated the dose requirements for sustained in vivo activity of ofatumumab, a human anti‐CD20 antibody under development for the treatment of B…”
Get full text